Capecitabine Tablet, Film Coated
Product Images NDC 72205-006

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 72205-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mg-60s (Capcetabine 150mg 60s Count)

Label for Capecitabine 150 mg film-coated tablets, USP, packaged as 60 tablets. This oral prescription drug is manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC. The label includes dosing and storage instructions, NDC 72205-006-60, and a barcode.*

FDA Label Image

500mg-120s (Capcetabine 500mg 120s Count)

Capecitabine 500 mg film-coated tablets label showing a 120-tablet count. The label includes dosage form, strength, and manufacturer information, with Novadoz Pharmaceuticals LLC as the distributor. It features storage instructions, pharmacist guidance to dispense the patient information leaflet, and barcodes. The label also notes the manufacturer as MSN Laboratories Private Limited, India.*

FDA Label Image

Fig-01 (Capecitabine Figure 01)

A survival curve chart comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line) over months since randomization. The y-axis represents survival probability from 0 to 1, and the x-axis shows time in months up to 96. Numbers at risk are provided below the x-axis for each group at various time points.*

FDA Label Image

Fig-02 (Capecitabine Figure 02)

A Kaplan-Meier survival curve comparing two treatment groups: Capecitabine and 5-FU + Leucovorin. The y-axis shows survival probability from 0 to 1, and the x-axis shows months since randomization, ranging from 0 to 96 months. The solid line represents Capecitabine, and the dashed line represents 5-FU + Leucovorin, with survival probabilities declining over time for both groups. A table below indicates the number of patients at risk at various time points for both groups.*

FDA Label Image

Fig-03 (Capecitabine Figure 03)

A survival probability curve comparing two treatment groups over time in days. The graph plots estimated probability on the y-axis against time on the x-axis, showing one group treated with 5-FU plus Leucovorin (Mayo Regimen) and another with Capecitabine 1250 mg/sqm twice daily intermittent dosing. Both treatment groups display a similar decreasing survival probability over approximately 1500 days.*

FDA Label Image

Fig-4 (Capecitabine Figure 04)

A Kaplan-Meier survival curve comparing the estimated probability over time (days) of two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1,250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph displays survival probabilities from 0 to 800 days, with group curves indicating differences in survival outcomes.*

FDA Label Image

Fig-5 (Capecitabine Figure 05)

A Kaplan-Meier survival curve showing estimated probability over time (days) comparing two treatment groups: Docetaxel 100 mg/sqm every three weeks (dashed line) and Capecitabine 1,250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every three weeks (solid line). The graph displays survival probabilities up to 800 days with marked median survival times around 351.5 and 442 days for each group, respectively.*

FDA Label Image

For (Capecitabine Formula)

Chemical structures and enzymatic conversion pathway of Capecitabine showing its transformation to 5'-DFCR, then to 5'-DFUR, and finally to 5-FU. Each compound is depicted with molecular structures and arrows indicate enzymatic steps catalyzed by carboxylesterase, Cyd deaminase, and dThdPase.*

FDA Label Image

Stru (Capecitabine Structure)

Chemical structure of the active ingredient Capecitabine, showing its molecular composition with marked atoms and bonds typical of the compound's cytidine analog structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.